Table 2.
Incidence and demographic data according to different interpretations of the criteria for KDIGO AKI stage ≥ 2.
| Criterion | Incidence of AKI (%) | Age (mean ± SD) | Admission SOFA score (mean ± SD) | Weight, kg (mean ± SD) | Baseline SCrea value, mg/dl (mean ± SD) | Urinary catheter (%) | Gender (% male) | Chronic kidney disease (%) | Diabetes (%) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AKI | No AKI | AKI | No AKI | AKI | No AKI | AKI | No AKI | AKI | No AKI | AKI | No AKI | AKI | No AKI | AKI | No AKI | ||
| SCrea | 13.2 | 62.3 ± 15.1 | 60.6 ± 17.0 | 9.2 ± 4.5 | 6.7 ± 4.0 | 79.0 ± 17.6 | 75.6 ± 16.5 | 2.73 ± 3.12 | 1.05 ± 2.59 | 66.0 | 61.6 | 43.9 | 12.0 | 22.0 | 15.4 | ||
| UO-1 | 34.3 | 64.1 ± 15.4 | 59.1 ± 17.2 | 8.6 ± 4.3 | 6.2 ± 3.8 | 81.4 ± 17.8 | 73.2 ± 15.3 | 86.2 | 81.4 | 66.6 | 59.9 | 20.3 | 14.1 | 20.1 | 14.2 | ||
| UO-2 | 14.2 | 63.6 ± 15.6 | 60.3 ± 16.9 | 9.0 ± 4.6 | 6.7 ± 4.0 | 82.7 ± 19.3 | 74.9 ± 15.9 | 83.4 | 83.8 | 65.1 | 61.8 | 27.5 | 14.4 | 20.7 | 15.5 | ||
| SCrea-UO-1 | 38.7 | 63.3 ± 15.6 | 59.2 ± 17.3 | 8.4 ± 4.3 | 6.2 ± 3.8 | 80.7 ± 17.7 | 73.1 ± 15.2 | 66.4 | 59.6 | 25.3 | 10.6 | 19.9 | 13.9 | ||||
| SCrea-UO-2 | 20.9 | 62.4 ± 15.7 | 60.4 ± 17.0 | 8.6 ± 4.5 | 6.6 ± 3.9 | 80.7 ± 18.6 | 74.8 ± 15.9 | 65.2 | 61.4 | 35.1 | 11.3 | 20.3 | 15.2 | ||||
SCrea: serum creatinine > 4.0 mg/dl or > 2 × baseline, where baseline = SCrea-1 whenever available, otherwise SCrea-2, or SCrea-3 (when neither SCrea-1 nor SCrea-2 are available) with Screa-1 defined as baseline Screa measurement as manually entered in ICIS by the treating physician at ICU admission; Screa-2 defined as the lowest pre-ICU measurement up to 365 days before ICU admission as extracted from the lab information system; Screa-3 defined as a back-calculated baseline Screa using the simplified 4-variable Modification of Diet in Renal Disease (MDRD) Study equation assuming an estimated glomerular filtration rate (eGFR) of 75 ml/min/1.73 m2 for every patient30; UO-1: total UO during the last 12-h period was ≤ 6 ml/kg; UO-2: total UO during each of the last 12 consecutive 1-h periods was ≤ 0.5 ml/kg; SCrea-UO-1: AKI stage ≥ 2 according to either the SCrea criterion or the UO-1 criterion; SCrea-UO-2: AKI stage ≥ 2 according to either the SCrea criterion or the UO-2 criterion.